Nob Hill Therapeutics is a respiratory-focused healthcare company developing high-dose lung delivery technologies and therapeutics. It holds a patented Dry Powder Nebulizer platform that generates drug aerosols and delivers them to the lower respiratory tract independent of patient lung capacity. The company's patent-protected inhalation device can deliver high therapeutic doses directly to the lung and is designed for patients of all ages, including those with compromised lung function. Led by CEO Noel Greenberger and based in Albuquerque, NM, NHT plans to advance its technology and therapeutics toward regulatory milestones. The company recently raised $3M in Series A financing to fund continued development of its high-dose respiratory technology and pre-IND studies. Nob Hill Therapeutics is developing a patent‑protected DryNeb dry powder nebulizer platform designed to deliver high therapeutic doses directly to the lower respiratory tract. The device is intended to be suitable for patients of all ages and inhalation capabilities and is claimed to generate highly efficient drug aerosols independent of lung capacity. The company is using the platform to develop inhaled anti‑infective therapies, including an inhaled treatment for lung fungal infection. NHT was awarded an HHS Phase II SBIR grant of up to $1.73M to fund drug powder formulation, DryNeb device development, and other pre‑IND studies. This Phase II award builds on a successful Phase I grant and encouraging animal efficacy results reported the prior year. NHT is a VIC Technology Venture Development portfolio company and recently appointed Noel Greenberger as CEO effective September 1, 2022. The company is based in Albuquerque, N.M.

Total raised

$5M

Funding rounds

2

Latest round

Series A

Latest activity

Aug 2024